These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Epothilones: mechanism of action and biologic activity. Goodin S; Kane MP; Rubin EH J Clin Oncol; 2004 May; 22(10):2015-25. PubMed ID: 15143095 [TBL] [Abstract][Full Text] [Related]
6. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Bollag DM; McQueney PA; Zhu J; Hensens O; Koupal L; Liesch J; Goetz M; Lazarides E; Woods CM Cancer Res; 1995 Jun; 55(11):2325-33. PubMed ID: 7757983 [TBL] [Abstract][Full Text] [Related]
7. Potential mechanisms of resistance to microtubule inhibitors. Kavallaris M; Annereau JP; Barret JM Semin Oncol; 2008 Jun; 35(3 Suppl 3):S22-7. PubMed ID: 18538175 [TBL] [Abstract][Full Text] [Related]
8. Effects of the antimitotic natural product dolastatin 10, and related peptides, on the human malarial parasite Plasmodium falciparum. Fennell BJ; Carolan S; Pettit GR; Bell A J Antimicrob Chemother; 2003 Apr; 51(4):833-41. PubMed ID: 12654761 [TBL] [Abstract][Full Text] [Related]
9. [Development of antituberculous drugs: current status and future prospects]. Tomioka H; Namba K Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921 [TBL] [Abstract][Full Text] [Related]
10. Microtubule active agents: beyond the taxane frontier. Morris PG; Fornier MN Clin Cancer Res; 2008 Nov; 14(22):7167-72. PubMed ID: 19010832 [TBL] [Abstract][Full Text] [Related]
11. Novel agents that target tublin and related elements. Rowinsky EK; Calvo E Semin Oncol; 2006 Aug; 33(4):421-35. PubMed ID: 16890797 [TBL] [Abstract][Full Text] [Related]
12. Natural products as antimitotic agents. Dall'Acqua S Curr Top Med Chem; 2014; 14(20):2272-85. PubMed ID: 25434355 [TBL] [Abstract][Full Text] [Related]
13. Microtubules: a dynamic target in cancer therapy. Pasquier E; Kavallaris M IUBMB Life; 2008 Mar; 60(3):165-70. PubMed ID: 18380008 [TBL] [Abstract][Full Text] [Related]
14. Mechanism of action of the unusually potent microtubule inhibitor cryptophycin 1. Panda D; Himes RH; Moore RE; Wilson L; Jordan MA Biochemistry; 1997 Oct; 36(42):12948-53. PubMed ID: 9335554 [TBL] [Abstract][Full Text] [Related]
15. Tubulin as a target for anticancer drugs. von Angerer E Curr Opin Drug Discov Devel; 2000 Sep; 3(5):575-84. PubMed ID: 19649885 [TBL] [Abstract][Full Text] [Related]
16. Epothilones as lead structures for the synthesis-based discovery of new chemotypes for microtubule stabilization. Feyen F; Cachoux F; Gertsch J; Wartmann M; Altmann KH Acc Chem Res; 2008 Jan; 41(1):21-31. PubMed ID: 18159935 [TBL] [Abstract][Full Text] [Related]
17. Targeting the microtubules in breast cancer beyond taxanes: the epothilones. Cortes J; Baselga J Oncologist; 2007 Mar; 12(3):271-80. PubMed ID: 17405891 [TBL] [Abstract][Full Text] [Related]